Last updated: September 5, 2026

Aspirin is an ultra-mature, low-cost pharmaceutical and over-the-counter product with negligible patent protection, broad global manufacturing capacity, and durable demand in analgesia, antiplatelet therapy, and combination products. Its financial trajectory depends on volume, brand positioning, hospital supply, and formulation differentiation rather than exclusivity.

Carisoprodol is also a fully generic drug, but its market is narrower and more exposed to regulatory controls, abuse concerns, prescribing restrictions, and competition from other skeletal-muscle relaxants. Both products lack meaningful originator exclusivity. Neither has a conventional branded-drug growth profile.

What is the current market position of aspirin?

Aspirin, or acetylsalicylic acid, is sold in prescription, OTC, hospital, and combination-product channels. Key indications include pain, fever, inflammation, acute coronary syndrome, and secondary cardiovascular prevention. The U.S. market includes immediate-release tablets, chewable tablets, enteric-coated tablets, suppositories, powders, and combination products.

Aspirin’s commercial position is defined by:

Extremely low unit cost
Global availability from multiple manufacturers
Strong consumer recognition
Extensive use in cardiovascular protocols
Declining reliance on aspirin for primary prevention in some patient groups
Continued demand in acute coronary syndrome and secondary prevention
Competition from acetaminophen, ibuprofen, naproxen, and branded combinations

The U.S. Preventive Services Task Force recommends selective rather than routine initiation of low-dose aspirin for primary prevention in certain adults because bleeding risk can outweigh cardiovascular benefit. The recommendation does not eliminate aspirin’s role in secondary prevention or emergency treatment of suspected myocardial infarction. (U.S. Preventive Services Task Force, 2022; American College of Cardiology/American Heart Association, 2019)

How does aspirin generate revenue?

Aspirin revenue is distributed across many low-value transactions rather than concentrated in a single patented product. The main commercial channels are:

Channel	Commercial role	Pricing profile
OTC analgesic tablets	Consumer pain and fever treatment	Highly price competitive
Low-dose cardiovascular tablets	Chronic prevention and hospital protocols	Low price, high repeat use
Combination analgesics	Migraine, cold, and pain products	Higher value per package
Hospital and institutional supply	Acute coronary syndrome and inpatient use	Contract-driven, low margin
Branded consumer products	Bayer and private-label positioning	Brand premium varies by market
Emerging-market distribution	Broad analgesic and cardiovascular use	Volume-led growth

Standalone aspirin product revenue is difficult to isolate because manufacturers often report aspirin within broader consumer-health, OTC, or pharmaceutical portfolios. Public-company filings generally do not disclose global aspirin sales as a separate line item.

What is the financial trajectory for aspirin?

Aspirin has a mature, defensive financial profile rather than a high-growth profile. Nominal revenue can rise through inflation, package-size changes, premium branding, and geographic expansion, but generic price competition limits margin expansion.

The most likely trajectory is:

Stable or modestly declining unit volume in high-income markets.
Continued growth in selected emerging markets.
Lower primary-prevention demand where clinical guidelines have changed.
Durable secondary-prevention and hospital demand.
Margin pressure from retailer private labels and procurement contracts.
Selective premium pricing for enteric-coated, chewable, buffered, and combination formulations.

Aspirin’s financial resilience comes from scale and low manufacturing cost. Its weakness is the absence of meaningful differentiation for standard tablets. Manufacturers that rely only on basic aspirin tablets have limited pricing power.

Which companies compete in the aspirin market?

Competition is fragmented. Relevant manufacturers and brand owners include:

Bayer, particularly through the Bayer Aspirin brand
Perrigo and private-label OTC suppliers
Teva Pharmaceutical Industries
Dr. Reddy’s Laboratories
Sandoz
Hikma Pharmaceuticals in selected prescription and hospital channels
Regional manufacturers in Asia, Latin America, and Europe
Contract manufacturers supplying retailers and pharmacy chains

The competitive landscape is not controlled by a single global patent holder. Purchasing contracts, regulatory registrations, product reliability, packaging, distribution, and retailer relationships often matter more than intellectual property.

What patents protect aspirin?

No meaningful composition-of-matter patent protects aspirin. Acetylsalicylic acid was synthesized in the 19th century, and any original patent rights expired long ago.

What formulation patents cover aspirin?

Potentially relevant rights may attach to specific products rather than aspirin itself. These can include:

Enteric-coating systems
Effervescent formulations
Buffered tablets
Chewable formulations
Controlled-release delivery
Combination products
Packaging or stability systems
Manufacturing processes

Such rights generally do not prevent competitors from selling ordinary immediate-release aspirin tablets. A manufacturer can avoid infringement risk by using a different formulation, coating, excipient system, or manufacturing process.

Aspirin combination products may have had more recent patents, but protection depends on the specific active ingredients and dosage form. A patent covering an aspirin-acetaminophen combination, for example, would not block plain aspirin.

What is the Orange Book status of aspirin?

The FDA Orange Book is most relevant to approved prescription drug products. Standard OTC aspirin marketed under the FDA OTC monograph system generally does not depend on Orange Book-listed patents. Prescription aspirin products and aspirin-containing combinations can appear in FDA databases under individual applications, but the active ingredient itself has no commercially meaningful exclusivity.

When does aspirin lose exclusivity?

Aspirin lost basic exclusivity more than a century ago. Current commercial barriers are regulatory and operational rather than patent-based.

Protection category	Aspirin status
Composition patent	Expired
Basic method-of-use protection	Expired or unavailable for ordinary indications
FDA new chemical entity exclusivity	Not applicable
Standard OTC monograph access	Available if product complies with applicable requirements
Formulation protection	Possible for narrow products
Trademark protection	Continues for brand names
Manufacturing know-how	May remain proprietary but is not product exclusivity

What is the current market position of carisoprodol?

Carisoprodol is a centrally acting skeletal-muscle relaxant approved for short-term treatment of acute, painful musculoskeletal conditions, generally alongside rest and physical therapy. It is metabolized to meprobamate, a controlled substance with sedative and abuse potential. In the United States, carisoprodol is a Schedule IV controlled substance. (U.S. Food and Drug Administration, 2023a; Drug Enforcement Administration, n.d.)

Carisoprodol is sold primarily as generic tablets, including 250 mg and 350 mg strengths. Some products combine carisoprodol with aspirin and caffeine. The branded Soma product historically established the category, but current U.S. demand is predominantly generic.

Its commercial position is constrained by:

Schedule IV control in the United States
Dependence and misuse risk
Sedation and impairment warnings
Short recommended treatment duration
Generic competition
Clinical preference for alternative muscle relaxants in many settings
State-level prescribing restrictions and opioid-related monitoring
Limited suitability for chronic treatment

How does carisoprodol generate revenue?

Carisoprodol revenue comes mainly from generic prescription tablets. The product has limited ability to command a brand premium because multiple manufacturers supply equivalent strengths and dosage forms.

The principal commercial channels are:

Retail pharmacy prescriptions
Workers’ compensation and musculoskeletal injury treatment
Primary-care and urgent-care prescribing
Generic combination products
Institutional and regional pharmacy contracts
Non-U.S. markets with different controlled-substance classifications

Revenue is sensitive to prescription volume, generic reimbursement, wholesaler pricing, and state monitoring rules. Manufacturer-level sales are rarely disclosed separately because carisoprodol is generally grouped within generic pharmaceuticals.

What is the financial trajectory for carisoprodol?

Carisoprodol has a mature-to-declining financial profile in the United States. The product can generate recurring generic revenue, but demand is limited by safety concerns and prescribing controls.

The main financial drivers are:

Prescription volume
Generic selling price
Number of approved manufacturers
Controlled-substance compliance costs
State restrictions
Competition from cyclobenzaprine and methocarbamol
Demand for combination products
Changes in payer reimbursement

Generic entry tends to reduce price rapidly when several suppliers participate. A manufacturer can improve economics through reliable supply, contract access, shortage participation, or a differentiated dosage form, but standard carisoprodol tablets have limited long-term pricing power.

Carisoprodol’s international trajectory is less uniform. Some markets permit broader use, while others restrict or prohibit the drug because of abuse, dependence, or meprobamate-related concerns. Geographic growth therefore depends on local registration, controlled-substance rules, and pharmacovigilance requirements.

What patents protect carisoprodol?

No meaningful composition-of-matter patent protects carisoprodol today. The drug was introduced in the late 1950s, and original patent rights and regulatory exclusivities expired decades ago.

Possible later rights may concern:

Fixed-dose combinations
Modified-release tablets
Specific excipient systems
Manufacturing processes
Stability improvements
Packaging or abuse-deterrent designs

These rights would be narrow and product-specific. They would not prevent a company from marketing conventional immediate-release carisoprodol tablets that comply with FDA requirements.

What is the Orange Book status of carisoprodol?

Carisoprodol tablets are generic prescription products. The original branded product was approved long before current generic market conditions, and any original exclusivity has expired. The commercially relevant question is not whether carisoprodol has active compound protection. It is whether a particular generic applicant has an approved product, acceptable manufacturing controls, and access to controlled-substance distribution channels.

When does carisoprodol lose exclusivity?

Carisoprodol lost its original exclusivity many years ago. There is no active compound-level exclusivity that materially limits generic competition.

Protection category	Carisoprodol status
Original compound patent	Expired
Original brand exclusivity	Expired
FDA new chemical entity exclusivity	Expired
Standard generic entry	Available
Formulation patents	Possible but narrow
Method-of-use patents	No meaningful blocking protection for ordinary use
Controlled-substance regulation	Active commercial constraint
Trademark protection	May remain for brand names but does not block generic substitution

How does aspirin compare with carisoprodol?

Factor	Aspirin	Carisoprodol
Primary category	Analgesic and antiplatelet	Skeletal-muscle relaxant
Market maturity	Extremely mature	Mature
Patent protection	None at compound level	None at compound level
U.S. regulatory status	OTC and prescription uses	Prescription Schedule IV
Main demand driver	Pain, cardiovascular prevention, hospital use	Short-term acute musculoskeletal treatment
Pricing power	Very low for basic tablets	Low for standard generics
Abuse risk	Minimal	Material
Generic competition	Very broad	Broad but more regulated
Growth opportunity	Emerging markets and differentiated products	Limited, with selected international opportunities
Main commercial risk	Commodity pricing and guideline shifts	Controlled-substance restrictions and declining prescribing
Revenue visibility	High volume, low value	Lower volume, prescription-dependent

Aspirin has the stronger long-term demand base because it serves both consumer and institutional markets. Carisoprodol has a narrower addressable market and greater regulatory exposure. Aspirin is more likely to remain commercially durable, while carisoprodol is more vulnerable to prescribing declines.

Which companies are challenging aspirin and carisoprodol exclusivity?

Neither product has a meaningful current Paragraph IV battleground comparable to a recently patented branded drug. Because compound-level protection has expired, generic manufacturers generally do not need to challenge an active patent to enter the standard market.

What is the Paragraph IV status of aspirin?

For ordinary aspirin products, Paragraph IV litigation is not commercially central. A Paragraph IV certification may arise for a particular patented formulation or combination product, but it would concern that narrow product rather than aspirin as an active ingredient.

What is the Paragraph IV status of carisoprodol?

The same analysis applies to carisoprodol. Any Paragraph IV dispute would likely involve a specific combination, modified-release product, or other formulation. Standard immediate-release carisoprodol tablets face no meaningful compound patent barrier.

What patent litigation and settlement agreements affect these drugs?

There is no current, widely recognized originator-versus-generic patent dispute that materially restricts ordinary aspirin or carisoprodol access in the United States. Historical disputes have generally involved branded formulations, combinations, labeling, manufacturing, or marketing conduct rather than the basic molecules.

Settlement agreements are therefore unlikely to influence the broad market in the way they do for protected products. The relevant legal exposure is more likely to involve:

Product liability
Controlled-substance compliance
False or misleading promotion
Manufacturing quality
Labeling
Supply contracts
Trademark disputes
Antitrust claims involving distribution or private-label arrangements

What regulatory risks affect future sales?

Aspirin regulatory risks

Aspirin faces relatively low regulatory risk for ordinary OTC products, but manufacturers must comply with:

OTC monograph requirements
Good manufacturing practice rules
Labeling and dosing requirements
Combination-product regulations
Adverse-event reporting
Pediatric and bleeding-risk warnings
Quality and stability standards

The main demand risk is clinical guidance that reduces aspirin use for primary prevention. That risk is partly offset by continuing use in secondary prevention and emergency cardiovascular care.

Carisoprodol regulatory risks

Carisoprodol faces materially higher regulatory risk. Manufacturers and distributors must manage:

Schedule IV controlled-substance requirements
Prescription monitoring programs
Diversion controls
Suspicious-order monitoring
Pharmacovigilance
Abuse and dependence warnings
Impairment and sedation risks
State prescribing limits
Potential federal or state reclassification pressure

A regulatory action affecting the entire class could reduce demand quickly. Enforcement risk also increases compliance costs for wholesalers, pharmacies, and manufacturers.

What manufacturing and intellectual-property barriers exist?

Aspirin manufacturing is technically established and widely available. The main barriers are:

Reliable pharmaceutical-grade raw materials
Control of hydrolysis and moisture sensitivity
Tablet uniformity
Coating performance
Packaging stability
Regulatory registrations
Distribution scale

Carisoprodol manufacturing is also established, but controlled-substance handling creates additional requirements. Manufacturers need secure inventory controls, documentation, validated processes, and compliant distribution. These requirements can reduce the number of credible suppliers even when patent barriers are absent.

Neither drug has a strong manufacturing moat comparable to complex biologics, sterile injectables, or highly specialized drug-device products. The strongest advantages are scale, quality history, regulatory compliance, supply reliability, and channel access.

What generic launch scenarios exist for aspirin and carisoprodol?

Aspirin launch scenarios

A new aspirin supplier would most likely enter through:

Private-label OTC tablets.
Low-dose cardiovascular products.
Chewable or enteric-coated products.
Hospital and institutional contracts.
Combination analgesics.
Emerging-market registrations.

Success would depend on cost, retailer access, packaging, and supply consistency. A plain-tablet launch would face intense price competition.

Carisoprodol launch scenarios

A new carisoprodol supplier would most likely enter through:

Standard 250 mg or 350 mg tablets.
Authorized generic or contract supply.
Combination products containing aspirin and caffeine.
Regional pharmacy and institutional contracts.
Markets with less restrictive controlled-substance rules.

The principal risk is insufficient volume after price erosion. A supplier also needs controlled-substance compliance infrastructure, which raises operating costs relative to ordinary generic tablets.

What licensing deals are relevant to aspirin and carisoprodol?

Licensing is not a major value driver for either molecule. Commercial arrangements are more likely to involve:

Private-label supply
Contract manufacturing
Authorized generics
Regional distribution
Brand licensing
Combination-product commercialization
Hospital procurement agreements

Aspirin has greater potential for brand licensing and consumer-health partnerships. Carisoprodol licensing is more likely to involve regional rights or generic supply because the molecule has little standalone differentiation.

Key Takeaways

Aspirin has no meaningful compound-level patent protection and remains a global commodity pharmaceutical.
Aspirin’s demand is supported by secondary cardiovascular prevention, acute coronary syndrome treatment, analgesia, and combination products.
Aspirin’s financial profile is high-volume and low-margin, with modest growth potential in emerging markets and differentiated formulations.
Carisoprodol also has no meaningful compound-level exclusivity and is supplied mainly by generic manufacturers.
Carisoprodol has a narrower market, lower prescribing durability, and higher regulatory exposure because it is a Schedule IV controlled substance in the United States.
Neither product has a significant current Paragraph IV or patent-litigation barrier for standard tablets.
Manufacturing scale, quality, controlled-substance compliance, distribution, and procurement access matter more than patents.
Aspirin has the stronger long-term commercial base. Carisoprodol faces greater downside from clinical restrictions, abuse concerns, and substitution by other muscle relaxants.
Product-level revenue estimates are generally unavailable because manufacturers report these products within broader OTC or generic portfolios.

Frequently Asked Questions

Is aspirin still a profitable pharmaceutical product?

Yes, but profitability depends on volume, manufacturing scale, brand positioning, and distribution. Standard aspirin tablets have low margins because multiple suppliers and private-label products compete on price.

Is carisoprodol being discontinued?

Carisoprodol remains available as a generic prescription drug in the United States. Availability can vary by manufacturer, pharmacy inventory, state restrictions, and controlled-substance distribution policies.

Can a company patent a new aspirin product?

A company generally cannot patent aspirin itself, but it may seek patents for a novel formulation, delivery system, combination, manufacturing process, or packaging configuration that meets patentability standards.

Is carisoprodol stronger than cyclobenzaprine?

The drugs have different pharmacologic profiles and tolerability considerations. Carisoprodol has greater controlled-substance and dependence concerns, while clinical selection depends on the condition, patient risk, treatment duration, and prescriber judgment.

Does aspirin have biosimilar competition?

No. Aspirin is a small-molecule drug, not a biologic. Competition occurs through generic, OTC, private-label, and combination products rather than the biosimilar pathway.

References

American College of Cardiology/American Heart Association. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation, 140(11), e596-e646.

Drug Enforcement Administration. (n.d.). Drug scheduling. U.S. Department of Justice. https://www.dea.gov/drug-information/drug-scheduling

U.S. Food and Drug Administration. (2023a). Soma (carisoprodol) prescribing information. https://www.accessdata.fda.gov

U.S. Food and Drug Administration. (2023b). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. Preventive Services Task Force. (2022). Aspirin use to prevent cardiovascular disease: Preventive medication. JAMA, 327(16), 1577-1584.

US Patents:	0
Tradenames:	5
Applicants:	8
NDAs:	10
DailyMed Link:	ASPIRIN; CARISOPRODOL at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Meda Pharms	SOMA COMPOUND W/ CODEINE	aspirin; carisoprodol; codeine phosphate	TABLET;ORAL	012366-002	Jul 11, 1983		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Oxford Pharms	CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE	aspirin; carisoprodol; codeine phosphate	TABLET;ORAL	040283-001	Dec 29, 1998		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Genus	CARISOPRODOL AND ASPIRIN	aspirin; carisoprodol	TABLET;ORAL	040116-001	Apr 25, 1996		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Oxford Pharms	CARISOPRODOL AND ASPIRIN	aspirin; carisoprodol	TABLET;ORAL	040252-001	Dec 10, 1997		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Meda Pharms	SOMA COMPOUND	aspirin; carisoprodol	TABLET;ORAL	012365-005	Jul 11, 1983	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Summary for ASPIRIN; CARISOPRODOL

Anatomical Therapeutic Chemical (ATC) Classes for ASPIRIN; CARISOPRODOL